Director, Quality Assurance – Clinical and Nonclinical Development at Prime Medicine

Watertown, Massachusetts, United States

Prime Medicine Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Gene EditingIndustries

Requirements

  • Hands-on QA experience in gene therapy modalities
  • Track record of sound judgment, collaborative decision making, and effective partnership with cross-functional teams
  • Ability to be onsite 2-3 days a week in Watertown, MA

Responsibilities

  • Define and implement the clinical and nonclinical quality strategy for Prime Medicine, embedding ICH E6(R3) and ICH M3(R2)/OECD principles from first-in-human through pivotal stages
  • Establish and maintain systems and processes (including SOP development) to improve the quality and compliance of both clinical and nonclinical studies, providing oversight and support to CRO GLP studies and internal non-GLP study activities in both the United States and Rest of World (ROW)
  • Partner tightly with Nonclinical, Clinical Operations, CMC, and Regulatory teams to make risk-balanced, time-bound decisions that protect subjects and program timelines
  • Maintain and advance the phase-appropriate Quality Management System (QMS) for GCP, applying proportionality to indication, phase, and patient risk; provide input to and perform reviews of Deviation, CAPA, and Change Management records
  • Ensure data capture, management and analysis is fit for purpose, including audit trail reviews and software assurance approaches to satisfy 21 CFR Part 11/EU Annex 11 compliance requirements
  • Support or lead QA audits and inspections of clinical and nonclinical sites, vendors and studies, ensuring appropriate follow-up and CAPA closure; contribute to the authoring, review, and revision of SOPs, templates, and procedural documents related to GLP and GCP activities
  • Ensure nonclinical study protocols are reviewed and approved on time, and that deviations from approved protocols are properly documented, evaluated, and reported
  • Implement systems and workflows to ensure that data in study reports are accurate, complete, and traceable through the ELN to raw data and animal subjects where applicable
  • Confirm that bioanalytical method qualification and validation studies are conducted in accordance with internal SOPs, ICH M10, and other applicable regulatory guidance; review bioanalytical method reports for clarity, traceability, and data integrity

Skills

Key technologies and capabilities for this role

Quality AssuranceGene TherapyClinical DevelopmentNonclinical DevelopmentRegulatory ComplianceData IntegrityRisk-Based QualityGCPGLP

Questions & Answers

Common questions about this position

Is this role remote or does it require onsite work?

The ideal candidate will be onsite 2-3 days a week in Watertown, MA.

What salary or compensation is offered for this position?

This information is not specified in the job description.

What experience and skills are required for this QA Director role?

The role requires hands-on QA experience in gene therapy modalities, a track record of sound judgment, collaborative decision making, and effective partnership with cross-functional teams.

What is the company culture like at Prime Medicine?

This information is not specified in the job description.

What makes a strong candidate for this Director, Quality Assurance position?

A strong candidate has hands-on QA experience in gene therapy, expertise in establishing risk-based quality frameworks, and the ability to partner strategically with Clinical Development and Nonclinical functions while demonstrating sound judgment and collaboration.

Prime Medicine

Gene editing technology for genetic diseases

About Prime Medicine

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, it emphasizes collaboration with research institutions and pharmaceutical companies to advance its technology and bring it to market through licensing agreements and partnerships. The leadership team has extensive experience in developing innovative medicines, and the company is committed to enhancing its technological capabilities.

Cambridge, MassachusettsHeadquarters
2019Year Founded
$306.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Flexible Work Hours

Risks

Intellectual property disputes may lead to costly legal battles and delays.
The competitive landscape in gene editing is intensifying, challenging Prime Medicine's market position.
Reliance on partnerships exposes Prime Medicine to risks if collaborations don't meet expectations.

Differentiation

Prime Editing offers precise DNA modifications without double-stranded breaks, unlike CRISPR.
Prime Medicine's technology can correct faulty DNA segments, restoring normal genetic function.
The company collaborates with top-tier partners like Bristol Myers Squibb for strategic growth.

Upsides

Prime Medicine secured $244.6M to advance its genetic therapies and pipeline.
The partnership with Bristol Myers Squibb includes potential milestone payments over $3.5 billion.
Growing interest in gene editing for rare diseases boosts investment and collaboration opportunities.

Land your dream remote job 3x faster with AI